Cynata Therapeutics

Gain a direct line to Cynata Therapeutics leadership

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Contact Us

Pre-Clinical Development

Clinical Development

Products & Pipeline

Scientific Publications

Intellectual Property

Cymerus™ Platform

Our technology

Board of Directors

About us

Company FAQs

Corporate Governance

Analyst Research

Investor FAQs

Financial Reports

Right to Receive Documents

Investor Presentations

Share Price

Announcements

Investors

Updates

Home

Frank Ruhl Libre

25-04-28_CYP - CYP Phase 2 aGvHD Trial 60 Recruited.pdf

This report has been prepared by Euroz Hartleys and solely reflects the views of Euroz Hartleys.

Any opinions, forecasts, recommendations or forward-looking statements in the report reflect the judgement and assumptions of Euroz Hartleys at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Euroz Hartleys update: "Phase 2 aGvHD Trial 60% Recruited"